Literature DB >> 33275490

Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.

Bishal Gyawali1,2,3, Howard Jack West4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33275490     DOI: 10.1200/JCO.20.01762

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Clinical Benefit Scales and Trial Design: Some Statistical Issues.

Authors:  Edward L Korn; Carmen J Allegra; Boris Freidlin
Journal:  J Natl Cancer Inst       Date:  2022-09-09       Impact factor: 11.816

2.  Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.

Authors:  Shannon S Zhang; Sai-Hong Ignatius Ou
Journal:  Lung Cancer (Auckl)       Date:  2022-04-26

3.  Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.

Authors:  David R Jones; Yi-Long Wu; Masahiro Tsuboi; Roy S Herbst
Journal:  J Thorac Cardiovasc Surg       Date:  2021-02-09       Impact factor: 6.439

Review 4.  Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.

Authors:  Kevin Chen; Misty D Shields; Pradeep S Chauhan; Ricardo J Ramirez; Peter K Harris; Melissa A Reimers; Jose P Zevallos; Andrew A Davis; Bruna Pellini; Aadel A Chaudhuri
Journal:  Mol Diagn Ther       Date:  2021-11-01       Impact factor: 4.476

5.  Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.

Authors:  Pengfei Zhao; Hongchao Zhen; Hong Zhao; Lei Zhao; Bangwei Cao
Journal:  BMC Cancer       Date:  2022-03-26       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.